Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone

Zaineb A F Albayati, Manjula Sunkara, Suzannah M. Schmidt-Malan, Melissa J. Karau, Andrew J. Morris, James M. Steckelberg, Robin Patel, Philip J. Breen, Mark S. Smeltzer, K. Grant Taylor, Kevyn E. Merten, William M. Pierce, Peter A. Crooks

Research output: Contribution to journalArticle

7 Scopus citations


We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.

Original languageEnglish (US)
Pages (from-to)1855-1868
Number of pages14
JournalAntimicrobial Agents and Chemotherapy
Issue number3
StatePublished - Mar 1 2016


ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Albayati, Z. A. F., Sunkara, M., Schmidt-Malan, S. M., Karau, M. J., Morris, A. J., Steckelberg, J. M., Patel, R., Breen, P. J., Smeltzer, M. S., Taylor, K. G., Merten, K. E., Pierce, W. M., & Crooks, P. A. (2016). Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone. Antimicrobial Agents and Chemotherapy, 60(3), 1855-1868.